A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Ascending Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Non-Japanese and Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2016
Price : $35 *
At a glance
- Drugs MLN 3126 (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions
- Sponsors Takeda
- 12 Mar 2016 Results of this and other trial (see profile 257229) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 09 Apr 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 09 Mar 2015 Status changed from active, no longer recruiting to suspended, according to ClinicalTrials.gov record.